Septerna

1 known investors

Septerna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline focuses on endocrinology, immunology and inflammation, and metabolic diseases for patients with unmet medical needs.

BiotechDeep Tech